Skip to main content

Table 1 Patients from whom virus isolates and/or infectious molecular clones were generated

From: Relative resistance of HIV-1 founder viruses to control by interferon-alpha

Patient ID

Transmission risk group1

Clade2

Setpoint VL (copies/ml)3

Virus isolation time-points (DFOSx)4

IMCs generated6

CH040

MSM

B

13,224

None

Founder7

CH058

MSM

B

260

285

Founder, 6-month7

CH077

MSM

B

3,631

215, 5925

Founder, 6-month7

CH162

HSX

C

114,815

None

Founder8

CH164

HSX

C

575,440

None

Founder8

CH185

HSX

C

40,738

None

Founder8

CH236

HSX

C

134,896

None

Founder, 6-month9

CH264

HSX

C

74,131

None

Founder9

CH470

MSM

B

23,442

335

Founder, 6-month10

CH850

HSX

C

15,488

None

Founder, 6-month9

MM23

MSM

B

82,958

14, 204, 631, 1535

None

MM24

MSM

B

128,021

16, 1322

None

MM25

MSM

B

72,600

10

None

MM26

MSM

B

34,493

69

None

MM27

MSM

B

48,360

28, 1516

None

MM28

MSM

B

12,322

6, 1995

None

MM33

MSM

B

73,958

12, 1912

None

MM34

MSM

B

8,522

25, 2227

None

MM38

MSM

B

ND

29

None

MM39

MSM

B

8,546

11, 1206

None

SUMA

MSM

B

17,245

None

Founder7

  1. 1Transmission risk group: MSM = men who have sex with men; HSX = heterosexual.
  2. 2Clade of infecting virus: all clade B virus infected patients were recruited from clinical sites in the UK or USA, whilst clade C virus infected patients were recruited from clinical sites in Africa.
  3. 3Setpoint persisting viral load established, calculated as described by Fellay et al.[65].
  4. 4Time-points during infection when plasma from which virus isolates were subsequently derived was cryopreserved, expressed as days following onset of symptoms of the acute retroviral syndrome (DFOSx); or 5for those patients where the time of onset of symptoms was not known, expressed as days post Fiebig stage I/II of acute infection [66].
  5. 6HIV-1 IMCs generated: founder = IMC corresponding to the deduced sequence of the founder virus that established systemic infection; 6-month = IMC corresponding to the 6-month consensus virus sequence.
  6. 7SGA and viral sequence analysis reported in [67]; construction of the founder IMC described in [68]; construction of the 6-month IMC described in [69].
  7. 8SGA, viral sequence analysis and construction of the founder IMC described in [70].
  8. 9SGA and viral sequence analysis, unpublished data of G.M. Shaw and B.H. Hahn; founder and 6-month IMC construction, unpublished data of C. Ochsenbauer and J.C. Kappes.
  9. 10SGA, viral sequence analysis and construction of the founder IMC described in [70]; 6-month IMC construction, unpublished data of C. Ochsenbauer and J.C. Kappes.